Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Descartes-08

Cell therapy (CAR-T) · Kills target cells, directed at BCMA (TNFRSF17) · developed by Cartesian Therapeutics

Phase 3 Most advanced trial

RNAC Developer

3 Registered trials

What is Descartes-08?

Descartes-08 is an autologous CAR-T cell therapy engineered to express a chimeric antigen receptor directed against BCMA. It is being studied in multiple myeloma, systemic lupus erythematosus, and myasthenia gravis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Decartes-08, Descartes 08
Drug type: Cell therapy (CAR-T)
Targets: BCMA (TNFRSF17) (antigen)
Mechanism: Kills target cells, directed at BCMA (TNFRSF17)
Therapy area: Immunology, Oncology
Developer: Cartesian Therapeutics (RNAC)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06799247	Phase 3	Myasthaenia Gravis	Active not recruiting	RNAC
NCT06038474	Phase 2	Systemic Lupus Erythematosus (SLE)	Active not recruiting	RNAC
NCT04816526	Phase 2	Myeloma Multiple	Terminated	RNAC

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Myasthaenia GravisSystemic Lupus Erythematosus (SLE)Myeloma Multiple

Other drugs acting on TNFRSF17

SEA-BCMA Phase 1

More from Cartesian Therapeutics

Descartes 30 Phase 1 Descartes-11 Phase 2 Descartes-15 Phase 1 Descartes-25 Phase 1

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the RNAC page.

Follow RNAC, the company behind Descartes-08

See RNAC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RNAC catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z